Gilead Sciences, Inc. (GILD) Shares Bought by Global X Management Co. LLC

Global X Management Co. LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.8% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,635 shares of the biopharmaceutical company’s stock after buying an additional 1,018 shares during the period. Global X Management Co. LLC’s holdings in Gilead Sciences were worth $894,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the business. Bank of New York Mellon Corp lifted its holdings in shares of Gilead Sciences by 9.8% in the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after purchasing an additional 2,727,063 shares in the last quarter. Parnassus Investments CA lifted its holdings in shares of Gilead Sciences by 37.4% in the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after purchasing an additional 4,556,901 shares in the last quarter. APG Asset Management N.V. lifted its holdings in shares of Gilead Sciences by 16.7% in the 1st quarter. APG Asset Management N.V. now owns 5,923,426 shares of the biopharmaceutical company’s stock worth $402,319,000 after purchasing an additional 849,741 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Gilead Sciences by 25.7% in the 1st quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock worth $354,070,000 after purchasing an additional 1,066,172 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Gilead Sciences by 26.9% in the 1st quarter. Swiss National Bank now owns 4,668,124 shares of the biopharmaceutical company’s stock worth $317,059,000 after purchasing an additional 989,400 shares in the last quarter. Hedge funds and other institutional investors own 73.98% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ GILD) opened at 82.14 on Monday. The stock has a market cap of $107.27 billion, a price-to-earnings ratio of 8.92 and a beta of 1.14. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The firm’s 50-day moving average price is $80.97 and its 200-day moving average price is $71.66.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter last year, the business posted $3.08 earnings per share. The firm’s revenue was down 8.2% on a year-over-year basis. On average, equities analysts predict that Gilead Sciences, Inc. will post $8.75 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.53%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s payout ratio is presently 22.58%.

WARNING: This story was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://transcriptdaily.com/2017/10/09/gilead-sciences-inc-gild-shares-bought-by-global-x-management-co-llc.html.

GILD has been the topic of a number of recent research reports. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Jefferies Group LLC restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 4th. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price objective on the stock in a research note on Monday, July 17th. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price objective on the stock. in a research note on Wednesday, June 21st. Finally, Deutsche Bank AG began coverage on Gilead Sciences in a research note on Friday, June 23rd. They set a “buy” rating and a $79.00 price objective on the stock. Twelve research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $85.66.

In related news, EVP Gregg H. Alton sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the completion of the sale, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the sale, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at $3,684,920. The disclosure for this sale can be found here. Over the last three months, insiders have sold 486,819 shares of company stock valued at $39,298,919. 1.30% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply